Skip to main content

Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone

Cancer Chemotherapy and Pharmacology volume 25, pages 135–138 (1989)Cite this article

Summary

A total of 40 patients with recurrent non-Hodgkin's lymphoma were treated with ABEP combination chemotherapy (aclarubicin,N 4-behenoyl-1-β-d-arabinofuranosylcytosine, etoposide, and prednisolone). A complete remission (CR) was achieved in 37.5% of the patients and partial remission, in 15.0%. The ABEP regimen proved to be effective in T-cell as well as B-cell lymphoma. It appears that the ABEP regimen may be partially non-cross-resistant with front-line doxorubicin-containing combinations. Survival for 39 months was achieved in 42.0% of the CR responders compared with 6.7% of partial responders (PRs) and nonresponders (NRs) (P<0.01). Diesease-free survival for 45 months was seen in 66% of the CR patients. The ABEP regimen was effective in the treatment of patients with recurrent or refractory lymphoma, enabling hope for long-term survival in the majority of CR cases.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Bonadonna G, Lattnada A, Banti A (1976) Recent trends in the treatment of non-Hodgkin's lymphomas. Eur J Cancer 12: 661

    Google Scholar 

  2. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T (1987) Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5: 407

    Google Scholar 

  3. Dantcher D, Slioussartchonk V, Paintrand M, Hayat M, Bourut C, Mathe G (1979) Electron microscopic studies of the skin after treatment of golden hamsters with Adriamycin, detorubicin, AD-32, and aclacinomycin. Cancer Treat Rep 63: 875

    Google Scholar 

  4. Egorin MJ, Clawson Re, Ross LH, Schlossberger NM, Bachur NR (1979) Cellular accumulation and disposition of aclacinomycin A. Cancer Res 39: 4396

    Google Scholar 

  5. Fisher RI, De Vita VT Jr, Hubbard SM, Longo DL, Wesley R, Chabner BA, Young RC (1983) Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMace and MOPP chemotherapy. Ann Intern Med 98: 304

    Google Scholar 

  6. Fujita H, Ogawa K, Kimura K (1983) In vivo distribution and activation of N4-behenoyl-1-β-d-arabinofuranosyl cytosine (BHAC). Chemotherapy 31: 723

    Google Scholar 

  7. Gehan EA (1965) A generalized two-sample Wilcoxon test for doubly censored data. Biometrika 52: 650

    Google Scholar 

  8. Harris AL, Potter C, Bunch C (1979) Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukemia. Br J Clin Pharmacol 8: 219

    Google Scholar 

  9. Horwich A, Peckham M (1983) “Bad risk” non-Hodgkin's lymphomas. Semin Hematol 20: 35

    Google Scholar 

  10. Issell BF, Crooke ST (1979) Etoposide (VP-16-213). Cancer Treat Rev 6: 107

    Google Scholar 

  11. Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, Butler JJ, Byrne GE, Moon TE, Fisher R, Haskins CL, Clotman CA (1979) Superiority of Adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma — a SWOG study. 43: 417

  12. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457

    Google Scholar 

  13. Kimura K, Ohno R, Amaki I, Hattori K, Hirota Y, Hoshino A, Ichimaru M, Ito M, Kimura I, Maekawa T, Masaoka T, Nakamura T, Ogawa M, Ohta K, Osamura S, Shimoyama M, Takaku F, Uzuka Y, Yamada K (1985) Treatment of acute myelogenous leukemia in adults withN 4-behenoyl-1-β-d-arabinofuranosylcytosine. Cancer 56: 1913

    Google Scholar 

  14. Klimo P, Connors JM (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102: 596

    Google Scholar 

  15. Nakamura T (1982) Action mechanism of antileukemic agents with special reference to nucleic acid metabolism of leukemic cells. Acta Haematol Jpn 45: 1203

    Google Scholar 

  16. Newcomer LN, Cadman EC, Nerenberg MI, Chen M, Bertino JR, Farber LR, Prosnitz LR (1982) Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisolone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma. Cancer Treat Rep 66: 1279

    Google Scholar 

  17. Ogawa M, Inagaki J, Horikoshi N, Inoue K, Chinen T, Ueoka H, Nagura E (1979) Clinical study of aclacinomycin A. Cancer Treat Rep 63: 931

    Google Scholar 

  18. Oki J (1980) Aclacinomycin A. In: Anthracyclines: current status and new developments. Academic, New York, p 323

    Google Scholar 

  19. Rwe JM, Chang AYC, Bennett JM (1988) Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia. Blood 71: 992

    Google Scholar 

  20. Schmoll HJ, Niederle N, Achterrath W (1981) Etoposide (VP16-213). Klin Wochenschr 59: 1177

    Google Scholar 

  21. Skarin AT, Canellos GP, Rosenthal DS, Case DC, MacIntyre JM, Pinkus GS, Moloney WC, Frei E (1983) Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1: 91

    Google Scholar 

  22. Sweet AT, Golomb HM, Ultmann JE, Miller JB, Stein RS, Lester EP, Mintz U, Bitram JD, Streuli RA, Daly K, Roth NO (1980) Cyclophosphamide, vincristine, methotrexate with leucovorin rescue and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med 92: 785

    Google Scholar 

  23. Traganos F, Staiano-Coico L, Darzynkiewitz Z, Melamed MR (1981) Effects of aclacinomycin on cell survival and cell cycle progression of cultured mammalian cells. Cancer Res 41: 2728

    Google Scholar 

  24. Ueda T, Nakamura T, Ando S, Kagawa D, Sasada M, Uchino H, Iohno I, Akiyama Y (1983) Pharmacokinetics of N4-behenoyl-1-β-d-arabinofuranosylcytosine in patients with acute leukemia. Cancer Res 43: 3412

    Google Scholar 

  25. Warrell RP, Danieu L, Coonley CJ, Atkins C (1987) Salvage chemotherapy of advanced lymphoma with investigational drugs: mitoguazone, gallium nitrate, and etoposide. Cancer Treat Rep 71: 47

    Google Scholar 

Download references

Author information

Affiliations

  1. The Third Department of Internal Medicine, Kanazawa University School of Medicine, 13-1 Takaramachi, 920, Kanazawa, Japan

    Takashi Yoshida, Shinobu Nakamura, Shigeki Ohtake, Kazumi Kobayashi, Masatoshi Kanno & Tamotsu Matsuda

  2. Wakamatsu National Hospital, Wakamatsu, Japan

    Sadaya Matano & Kunio Kondo

  3. Fukui Saiseikai Hospital, Fukui, Japan

    Kazuhiro Okafuji

  4. Tonami General Hospital, Tonami, Japan

    Masanobu Kanai & Rippo Sugimoto

  5. The First Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan

    Koichiro Egami & Hideyo Natori

Authors
  1. Takashi Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinobu Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeki Ohtake
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazumi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masatoshi Kanno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tamotsu Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sadaya Matano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kunio Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kazuhiro Okafuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masanobu Kanai
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Rippo Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Koichiro Egami
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hideyo Natori
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yoshida, T., Nakamura, S., Ohtake, S. et al. Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone. Cancer Chemother. Pharmacol. 25, 135–138 (1989). https://doi.org/10.1007/BF00692354

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00692354

Keywords

  • Lymphoma
  • Cancer Research
  • Prednisolone
  • Complete Remission
  • Etoposide